Results 11 to 20 of about 630 (147)

Posaconazole treatment of refractory eumycetoma and chromoblastomycosis Tratamento com posaconazol de casos de cromoblastomicose e micetoma maduromicótico resistentes a outros antifúngicos

open access: yesRevista do Instituto de Medicina Tropical de São Paulo, 2005
Eumycetoma and chromoblastomycosis are chronic, disfiguring fungal infections of the subcutaneous tissue that rarely resolve spontaneously. Most patients do not achieve sustained long-term benefits from available treatments; therefore, new therapeutic ...
Ricardo Negroni   +5 more
doaj   +2 more sources

Tratamiento antifúngico con posaconazol y anfotericina B en paciente con mucormicosis rinosinusal [PDF]

open access: yesPharmaceutical Care España, 2015
Introducción: La mucormicosis es una infección fúngica con elevada morbilidad y mortalidad. Se requiere tanto tratamiento quirúrgico como antifúngico, siendo el antimicótico de elección anfotericina B.
MT Martínez-Lazcano   +4 more
doaj   +5 more sources

Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis [PDF]

open access: yesBMC Microbiology
Pulmonary mucormycosis (PM), a life-threatening infection caused by Mucorales, exhibits high mortality. Comprehensive data integrating clinical profiling, antifungal susceptibility, and biofilm formation ability are limited.
Peng Wang   +9 more
doaj   +2 more sources

REVTRAIZOL Características e manejo da hepatotoxicidade em pacientes hospitalizados tratados com triazóis: uma revisão sistemática

open access: yesJornal de Assistência Farmacêutica e Farmacoeconomia
Introdução: As infecções fúngicas são as principais causas de morbidade e mortalidade em pacientes imunocomprometidos e gravemente hospitalizados.
Thamara da Silva Mamona   +3 more
doaj   +2 more sources

Posaconazole

open access: yesJournal of Postgraduate Medicine, 2010
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal ...
Bhattacharya, M.   +2 more
  +6 more sources

Early‐onset venous thromboembolisms in newly diagnosed non‐promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy

open access: yesEuropean Journal of Haematology, Volume 110, Issue 4, Page 426-434, April 2023., 2023
Abstract Objectives and Methods Venous thromboembolic (VTE) events are emerging as frequent complications in acute myeloid leukemia (AML); however, there is insufficient data regarding epidemiology, risk factors, and impact on outcomes. The optimal approach to balance risks of thrombosis and hemorrhage remains unclear.
Sebastian E. Koschade   +8 more
wiley   +1 more source

Relevancia clínica de la interacción entre posaconazol y digoxina: a propósito de un caso [PDF]

open access: yes, 2021
Resumen El posaconazol es un inhibidor de la glicoproteína P (P-gp), un transportador dependiente del ATP que desempeña un papel importante en la absorción, distribución y eliminación de múltiples medicamentos. Varios estudios in vitro han demostrado que
García Díaz,B   +3 more
core   +1 more source

Phäohyphomykose durch Cladosporium cladosporioides bei einem immunsupprimierten Jungen mit Ewing‐Sarkom

open access: yes, 2021
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 19, Issue 8, Page 1204-1206, August 2021.
Dorothea Kratzsch   +5 more
wiley   +1 more source

Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study

open access: yesSTEM CELLS Translational Medicine, Volume 9, Issue 10, Page 1190-1202, October 2020., 2020
A, In this clinical phase II study, 11 patients with severe, refractory chronic graft‐vs‐host disease (cGvHD) were treated with repeated monthly infusions of mesenchymal stromal cell (MSC). B, Six patients responded with a reduction in disease severity as measured by the National Institutes of Health score. Immunological analysis revealed that response
Erik Boberg   +9 more
wiley   +1 more source

Invasive pulmonary aspergillosis in heart transplant recipients: Is mortality decreasing?

open access: yesRevista Portuguesa de Cardiologia, 2021
Introduction: Infection remains a major complication among heart transplant (HT) recipients, causing approximately 20% of deaths in the first year after transplantation.
Eduardo Flores-Umanzor   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy